Orexo is a fully integrated specialty pharmaceutical company
Products approved worldwide
Our drug delivery technologies improve pharmaceuticals
Partnerships are critical to our success
We will be recognized for the added value our products bring to patients and societies
Orexo’s share is listed on Nasdaq Stockholm Mid Cap and available as American Depository Receipts (ADRs) on OTCQX in the US.
Follow Orexo in social media
In conjunction with the publishing of the Q218 report, Orexo are introducing “Orexo – our view”, where the aim is t… https://t.co/LnPf0Gt4Ve
Q218 #Orexo delivered one of the best Q ever in terms of net revenue growth of 25% and EBITDA of SEK 51m. The stron… https://t.co/539uaM4DBe
Next week, on July 11 at 8 am CET, #orexo announces the Q2 Interim Report. The same day at 2 pm we invite investors… https://t.co/Gihz8CJdp8
When you sign up to our newsletter or press releases, we use the data necessary for this purpose, or the data separately provided by you, to send you our email regularly. You can unsubscribe from our newsletter or press releases at any time via a link provided in the email.